These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8920208)

  • 1. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer.
    Denmeade SR; Isaacs JT
    Adv Pharmacol; 1996; 35():281-306. PubMed ID: 8920208
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin.
    Lin XS; Denmeade SR; Cisek L; Isaacs JT
    Prostate; 1997 Nov; 33(3):201-7. PubMed ID: 9365549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells.
    Tombal B; Weeraratna AT; Denmeade SR; Isaacs JT
    Prostate; 2000 Jun; 43(4):303-17. PubMed ID: 10861750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: complex regulation by intracellular calcium.
    Dubois C; Vanden Abeele F; Sehgal P; Olesen C; Junker S; Christensen SB; Prevarskaya N; Møller JV
    FEBS J; 2013 Nov; 280(21):5430-40. PubMed ID: 23927406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New strategies for the medical treatment of prostate cancer.
    Isaacs JT
    BJU Int; 2005 Dec; 96 Suppl 2():35-40. PubMed ID: 16359437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
    Christensen SB; Andersen A; Kromann H; Treiman M; Tombal B; Denmeade S; Isaacs JT
    Bioorg Med Chem; 1999 Jul; 7(7):1273-80. PubMed ID: 10465403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
    Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
    J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features.
    Engedal N; Saatcioglu F
    Prostate; 2001 Mar; 46(4):289-97. PubMed ID: 11241551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model.
    Muramaki M; Miyake H; Hara I; Kamidono S
    Int J Oncol; 2005 Mar; 26(3):623-8. PubMed ID: 15703816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line.
    McConkey DJ; Greene G; Pettaway CA
    Cancer Res; 1996 Dec; 56(24):5594-9. PubMed ID: 8971161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.
    Furuya Y; Lundmo P; Short AD; Gill DL; Isaacs JT
    Cancer Res; 1994 Dec; 54(23):6167-75. PubMed ID: 7954463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer.
    Denmeade SR; Isaacs JT
    Cancer J Sci Am; 1998 May; 4 Suppl 1():S15-21. PubMed ID: 9619266
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells.
    Humez S; Monet M; Legrand G; Lepage G; Delcourt P; Prevarskaya N
    Endocr Relat Cancer; 2006 Mar; 13(1):181-95. PubMed ID: 16601287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation.
    Bommareddy A; Rule B; VanWert AL; Santha S; Dwivedi C
    Phytomedicine; 2012 Jun; 19(8-9):804-11. PubMed ID: 22571975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of thapsigargin on Ca²+ fluxes and viability in human prostate cancer cells.
    Huang JK; Chou CT; Chang HT; Shu SS; Kuo CC; Tsai JY; Liao WC; Wang JL; Lin KL; Lu YC; Chen IS; Liu SI; Ho CM; Jan CR
    J Recept Signal Transduct Res; 2011 Jun; 31(3):247-55. PubMed ID: 21410406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation.
    Furuya Y; Isaacs JT
    Prostate; 1994 Dec; 25(6):301-9. PubMed ID: 7997434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
    Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
    Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques.
    Eaton JD; Perry MJ; Todryk SM; Mazucco RA; Kirby RS; Griffiths JR; Dalgleish AG
    Gene Ther; 2001 Apr; 8(7):557-67. PubMed ID: 11319623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apoptosis--principles and importance of programmed cell death for prostatic carcinoma].
    Gschwend JE
    Urologe A; 1996 Sep; 35(5):390-9. PubMed ID: 8999629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.
    Denmeade SR; Lin XS; Isaacs JT
    Prostate; 1996 Apr; 28(4):251-65. PubMed ID: 8602401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.